IRIS
SICURANZA, ANNA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.906
NA - Nord America 3.465
AS - Asia 1.790
SA - Sud America 344
AF - Africa 50
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 3
Totale 9.566
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.399
RU - Federazione Russa 1.113
GB - Regno Unito 715
SG - Singapore 654
IT - Italia 555
CN - Cina 549
IE - Irlanda 522
BR - Brasile 299
DE - Germania 271
SE - Svezia 211
HK - Hong Kong 155
FI - Finlandia 146
FR - Francia 137
VN - Vietnam 109
UA - Ucraina 92
KR - Corea 91
IN - India 63
CA - Canada 38
JP - Giappone 26
NL - Olanda 24
AR - Argentina 21
IR - Iran 19
PK - Pakistan 19
PL - Polonia 19
AT - Austria 18
BD - Bangladesh 18
ES - Italia 18
MX - Messico 18
TR - Turchia 18
ZA - Sudafrica 17
CZ - Repubblica Ceca 14
BE - Belgio 13
EG - Egitto 12
IQ - Iraq 11
SA - Arabia Saudita 9
AU - Australia 7
ID - Indonesia 7
MA - Marocco 7
AZ - Azerbaigian 5
CI - Costa d'Avorio 5
CO - Colombia 5
LT - Lituania 5
MY - Malesia 5
PT - Portogallo 5
BO - Bolivia 4
CH - Svizzera 4
EC - Ecuador 4
KZ - Kazakistan 4
BG - Bulgaria 3
CL - Cile 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
EE - Estonia 3
GR - Grecia 3
HR - Croazia 3
IL - Israele 3
JO - Giordania 3
SK - Slovacchia (Repubblica Slovacca) 3
UY - Uruguay 3
UZ - Uzbekistan 3
AE - Emirati Arabi Uniti 2
ET - Etiopia 2
EU - Europa 2
KE - Kenya 2
KG - Kirghizistan 2
LA - Repubblica Popolare Democratica del Laos 2
LK - Sri Lanka 2
MD - Moldavia 2
NP - Nepal 2
PA - Panama 2
PE - Perù 2
PH - Filippine 2
PY - Paraguay 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
A1 - Anonimo 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CR - Costa Rica 1
DK - Danimarca 1
GD - Grenada 1
JM - Giamaica 1
KH - Cambogia 1
LB - Libano 1
LU - Lussemburgo 1
LV - Lettonia 1
MK - Macedonia 1
MN - Mongolia 1
NZ - Nuova Zelanda 1
PS - Palestinian Territory 1
RO - Romania 1
RS - Serbia 1
TH - Thailandia 1
VE - Venezuela 1
Totale 9.566
Salva come PNG Salva come JPEG
Città #
Southend 624
Dallas 553
Dublin 518
Singapore 414
Fairfield 368
Moscow 307
Ashburn 303
Santa Clara 207
Chandler 185
Munich 162
Woodbridge 158
Hong Kong 155
Beijing 154
Siena 145
Hefei 131
Seattle 128
Wilmington 125
Cambridge 108
Houston 103
Helsinki 101
Ann Arbor 96
Seoul 90
New York 74
Jacksonville 72
Los Angeles 65
Princeton 63
Milan 53
Florence 52
São Paulo 38
Ho Chi Minh City 34
Dong Ket 31
Nanjing 29
Redondo Beach 25
Rome 25
The Dalles 25
London 24
Bengaluru 23
Shanghai 23
Dearborn 22
Tokyo 21
Turku 21
Buffalo 19
Nuremberg 19
Hanoi 18
Lauterbourg 17
San Mateo 17
Düsseldorf 16
Frankfurt am Main 16
Warsaw 16
Denver 15
Izmir 15
Portsmouth 15
San Diego 14
Washington 14
Boardman 12
Brussels 12
Johannesburg 12
Messina 12
Chennai 11
Lappeenranta 11
Stockholm 11
Turin 11
Brno 10
Montreal 10
San Francisco 10
Toronto 10
Brooklyn 9
Vienna 9
Atlanta 8
Chicago 8
Belo Horizonte 7
Boston 7
Columbus 7
Fremont 7
Nanchang 7
Orem 7
Poplar 7
Porto Alegre 7
Rio de Janeiro 7
Shenyang 7
Amsterdam 6
Cairo 6
Dhaka 6
Jinan 6
Kunming 6
Phoenix 6
Querétaro 6
Abidjan 5
Baku 5
Guangzhou 5
Guarulhos 5
Hangzhou 5
Hebei 5
Mumbai 5
Redwood City 5
Sacramento 5
Salvador 5
Taizhou 5
Tehran 5
Tianjin 5
Totale 6.409
Salva come PNG Salva come JPEG
Nome #
A novel class of oxazepine-based anti-cancer agents induces cell death in primary human CLL cells and efficiently reduces tumor growth in Eμ-TCL1 mice through the JNK/STAT4/p66Shc axis 293
Flow Cytometry Assessment of CD26+ Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia 283
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 278
Antibody and B-cell responses in myelofibrosis patients after the third doses of mRNA SARS-CoV-2 vaccines 272
A pilot monocentric analysis of efficacy and safety of Fludarabine-Campath combination (Flucam) as first line treatment in elderly patients with chronic lymphocytic leukaemia and Tp53 disfunction 271
Atherothrombotic Risk and TKIs Treatment In Chronic Myeloid Leukemia Patients: A Role For Genetic Predisposition and Pro-Inflammatory/Pro-Oxidative Status? 270
Residual peripheral blood CD26+leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission 269
Circulating CD34+/CD38-/CD26+ Leukemia Stem Cells along Chronic Myeloid Leukemia progression: differences between Chronic, Accelerated and Blast Phase 266
Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients 257
Atherothrombotic risk assessment during tyrosine kinase inhibitors treatment in chronic myeloid leukemia patients: new insight? 248
Insight into the behavior of hairy cell leukemia by immunogenetic analysis 225
Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients 223
Genetic predisposition and induced pro-inflammatory/pro-oxidative status may explain increased atherothrombotic risk during TKI treatment in chronic myeloid leukemia patients 222
Real-world experience with decitabine as a first-line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy 221
Study of gene polymorphisms as predictors of treatment efficacy and toxicity in patients with indolent non-hodgkin lymphomas and mantle cell lymphoma receiving bendamustine and rituximab 219
The Polycomb BMI1 Protein Is Co-expressed With CD26+ in Leukemic Stem Cells of Chronic Myeloid Leukemia 219
Lack of allelic exclusion by secondary rearrangements of tumour B-cell receptor light chains in hairy cell leukaemia 216
A case of acquired factor XIII deficiency secondary to plasmablastic lymphoma 204
Peptide vaccines for hematological malignancies: a missed promise? 201
Overview of Anti-SARS-CoV-2 Immune Response Six Months after BNT162b2 mRNA Vaccine 200
Molecular insight into the biology and clinical course of hairy cell leukemia utilizing immunoglobulin gene analysis 191
Antibody response in myelofibrosis patients after three doses of mRNA SARS-CoV-2 vaccine 189
Prognostic significance of lymphocyte/monocyte count and neutrophil/lymphocyte count in peripheral T cell lymphoma 181
First reported case of secondary mixed phenotype acute leukemia after multiple myeloma 181
Hodgkin lymphoma in the elderly: new perspectives and a 10-year monocenter real-life experience 175
Cladribine Efficacy in a Patient with Hairy Cell Leukemia and Severe Renal Insufficiency 165
Prognostic impact of tumor-associated macrophages, lymphocyte-to-monocyte and neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma 161
Minimal residual disease in multiple myeloma: State of the art and applications in clinical practice 159
Fludarabine, high-dose cytarabine and idarubicin-based induction may overcome the negative prognostic impact of FLT3-ITD in NPM1 mutated AML, irrespectively of FLT3-ITD allelic Burden 159
The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients 152
Prospective monitoring of Chronic Myeloid Leukemia Patients from Time of TKI Discontinuation: the fate of Peripheral Blood CD26+ Leukemia Stem Cells 151
Efficacy and safety of ruxolitinib for Covid-19 related acute respiratory distress syndrome in a patient with blastic plasmacytoid dendritic cell neoplasm (leukemic variant) 148
Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors 139
DART4MM: Daratumumab as Consolidation Therapy in Patients who Already Achieved Optimal Response/MRD Positivity by Next Generation Flow (NGF): Preliminary Results of a Phase 2 Multicenter Study 135
Peripheral Blood CD26+ Leukemia Stem Cells Monitoring in Chronic Myeloid Leukemia Patients from Diagnosis to Response to TKIs: Interim Results of a Multicenter Prospective Study (PROSPECTIVE FLOWERS) 134
Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study) 131
Favorable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib 128
Drug resistance and minimal residual disease in multiple myeloma 127
Long-term CR Multiple Myeloma Patients Show Cured or MGUS-like Minimal Residual Disease Pattern by Next Generation Flow 121
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors 118
Minimal Residual Disease Detection at RNA and Leukemic Stem Cell (LSC) Levels: Comparison of RT-qPCR, d-PCR and CD26+ Stem Cell Measurements in Chronic Myeloid Leukemia (CML) Patients in Deep Molecular Response (DMR) 117
The slower antibody response in myelofibrosis patients after two doses of MRNA sars-COV-2 vaccine calls for a third dose 116
CD26/DPP-4 in Chronic Myeloid Leukemia 115
Prospective Monitoring of Peripheral Blood CD26+ Leukemia Stem Cells in Chronic Myeloid Leukemia Patients from Time of TKI Discontinuation 113
Venetoclax in association with decitabine as effective bridge to transplant in a case of relapsed early T-cell lymphoblastic leukemia 111
Infectious complications after induction chemotherapy with FLAI(E) in newly diagnosed AML, omitting antibacterial prophylaxis 109
Longitudinal immunogenicity cohort study of SARS-CoV-2 mRNA vaccines across individuals with different immunocompromising conditions: heterogeneity in the immune response and crucial role of Omicron-adapted booster doses 109
Prognostic value of CD47 overexpression measured by flow cytometry in acute myeloid leukemia 109
The prognostic role of gene polymorphisms in patients with indolent non-Hodgkin lymphomas and mantle-cell lymphoma receiving bendamustine and rituximab: results of the 5-year follow-up study 106
Tumor-Associated Macrophages in Multiple Myeloma: Key Role in Disease Biology and Potential Therapeutic Implications 103
Are small lymphocytic lymphoma and chronic lymphocytic leukemia the same disease? The unsolved dilemma 102
Peripheral Blood Flow-Cytometry Chronic Myeloid Leukemia Stem Cells Detection and Quantification during Tyrosine Kinase Inhibitors Therapy 101
The role of tumor-associated macrophages in hematologic malignancies 96
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib 92
Intensive Fludarabine, High Dose Cytarabine and Idarubicin-Based Induction for Younger NPM1-Mutated AML Patient: Overcoming the Negative Prognosis of FLT3-ITD Mutation 89
Minimal Residual Disease Significance in Multiple Myeloma Patients Treated with Anti-CD38 Monoclonal Antibodies 81
Therapeutic Vaccinations with p210 Peptides in Imatinib-Treated Chronic Myeloid Leukemia Patients: 10 Years Follow-Up of GIMEMA CML0206 and SI0207 Studies 77
Unravelling a clinical role of peripheral blood leukemia stem cells at diagnosis in chronic myeloid leukemia patients: Final results of prospective FLOWERS study 32
Low rate of infectious mortality omitting fluoroquinolone prophylaxis in high-risk hematological patients, a single centre experience 27
The biology of chronic myeloid leukemia: an overview of the new insights and biomarkers 26
Tracking leukemic residuals: dissecting the inverse relationship between CD26+ stem cells and extracellular BCR::ABL1 transcript in Chronic Myeloid Leukemia (CML) 4
Totale 9.737
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.557
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.557
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021518 0 0 0 0 0 59 80 89 66 89 52 83
2021/2022609 42 71 33 55 39 18 26 18 42 41 108 116
2022/2023834 42 94 106 82 60 130 30 86 76 11 94 23
2023/20241.026 31 32 95 62 53 246 330 23 12 41 23 78
2024/20251.937 35 61 215 99 205 134 104 129 211 116 209 419
2025/20263.152 337 590 480 662 1.044 39 0 0 0 0 0 0
Totale 9.737